ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

ClinicalTrials.gov ID: NCT06843590

Public ClinicalTrials.gov record NCT06843590. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)

Study identification

NCT ID
NCT06843590
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
96 participants

Conditions and interventions

Interventions

  • ALKS 2680 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 21, 2025
Primary completion
May 31, 2026
Completion
May 31, 2026
Last update posted
Feb 11, 2026

2025 – 2026

United States locations

U.S. sites
32
U.S. states
18
U.S. cities
32
Facility City State ZIP Site status
Alkermes Investigator Site Cullman Alabama 35055 Recruiting
Alkermes Investigator Site Phoenix Arizona 85054 Recruiting
Alkermes Investigator Site Little Rock Arkansas 72211 Recruiting
Alkermes Investigator Site Los Angeles California 90025 Recruiting
Alkermes Investigator Site Redwood City California 94063 Recruiting
Alkermes Investigator Site San Francisco California 94143 Recruiting
Alkermes Investigator Site Colorado Springs Colorado 80918 Recruiting
Alkermes Investigator Site Brandon Florida 33511 Recruiting
Alkermes Investigator Site Miami Florida 33176 Recruiting
Alkermes Investigator Site Winter Park Florida 32789 Recruiting
Alkermes Investigator Site Atlanta Georgia 30328 Recruiting
Alkermes Investigator Site Macon Georgia 31210 Recruiting
Alkermes Investigator Site Stockbridge Georgia 30281 Recruiting
Alkermes Investigator Site Peoria Illinois 61637 Recruiting
Alkermes Investigator Site Kansas City Kansas 66160 Recruiting
Alkermes Investigator Site Lansing Michigan 48911 Recruiting
Alkermes Investigator Site Lincoln Nebraska 68506 Recruiting
Alkermes Investigator Site Middletown New Jersey 07748 Recruiting
Alkermes Investigator Site Denver North Carolina 28037 Recruiting
Alkermes Investigator Site Huntersville North Carolina 28078 Recruiting
Alkermes Investigator Site Canton Ohio 44718 Recruiting
Alkermes Investigator Site Cincinnati Ohio 45245 Recruiting
Alkermes Investigator Site Cleveland Ohio 44195 Recruiting
Alkermes Investigator Site Danville Pennsylvania 17822 Recruiting
Alkermes Investigator Site Philadelphia Pennsylvania 19107 Recruiting
Alkermes Investigator Site Wyomissing Pennsylvania 19610 Recruiting
Alkermes Investigator Site Columbia South Carolina 29201 Recruiting
Alkermes Investigator Site Austin Texas 78731 Recruiting
Alkermes Investigator Site San Antonio Texas 78229 Recruiting
Alkermes Investigator Site Sugar Land Texas 77478 Recruiting
Alkermes Investigator Site Sugarland Texas 77478 Recruiting
Alkermes Investigator Site Madison Wisconsin 53792 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06843590, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 11, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06843590 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →